LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Затворен

СекторЗдравеопазване

13.24 1.46

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.02

Максимум

13.33

Ключови измерители

By Trading Economics

Приходи

-9.7B

2.2B

Продажби

-11B

76B

P/E

Средно за сектора

24.556

49.888

Дивидентна доходност

0.63

Марж на печалбата

2.928

Служители

27,527

EBITDA

-13B

6.1B

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.63%

2.38%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

68M

11B

Предишно отваряне

11.78

Предишно затваряне

13.24

Настроения в новините

By Acuity

50%

50%

155 / 344 Класиране в Healthcare

Dr Reddy's Laboratories Ltd-ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.10.2025 г., 14:47 ч. UTC

Значими двигатели на пазара

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12.05.2026 г., 12:16 ч. UTC

Печалби

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12.05.2026 г., 12:16 ч. UTC

Печалби

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12.05.2026 г., 12:08 ч. UTC

Печалби

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12.05.2026 г., 12:06 ч. UTC

Печалби

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12.05.2026 г., 12:02 ч. UTC

Печалби

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12.05.2026 г., 12:01 ч. UTC

Печалби

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23.07.2025 г., 17:49 ч. UTC

Печалби

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23.07.2025 г., 17:48 ч. UTC

Печалби

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23.07.2025 г., 17:48 ч. UTC

Печалби

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Сравнение с други в отрасъла

Ценова промяна

Dr Reddy's Laboratories Ltd-ADR Прогноза

Консенсусна оценка

By TipRanks

Продай

1 ratings

0

Купи

0

Задържане

1

Продай

Настроение

By Acuity

155 / 344 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat